Rationale and Significance of Bispecific Antibody Development-Antibody Detection Service Topic-Tekbiotech-Yeast and Phage Display CRO, Expert in Nano-body and Antibody Drug Development

Rationale and Significance of Bispecific Antibody Development

Background

Monospecific antibodies (mAbs) function by inhibiting the overexpression of a specific signal or blocking a key pathway. However, cancer typically arises from multiple regulatory mechanisms. mAbs target only a single epitope, leading to a single function, and they rarely cure complex diseases like cancer. For example, a mAb might only label cancer cells but fail to activate T cell effector functions, resulting in weak therapeutic efficacy. To overcome these limitations, scientists have developed bispecific antibodies (bsAbs).

Development Rationale

1. Forced Proximity

The designed antibody can bind two different antigens: one end binds a specific antigen on the surface of a cancer cell, while the other end binds an activating receptor on the surface of an immune effector cell. Upon recognizing the cancer cell antigen, the bispecific antibody simultaneously engages the immune cell, potently activating the effector cell to kill the cancer cell.

2. Synergistic Blockade

Tumor cells often possess dual signaling pathways. When a monoclonal antibody binds to a specific antigen, it can only block one pathway, leaving the other to be compensatorily activated, leading to drug resistance. Bispecific antibodies, however, can simultaneously target two key points, more thoroughly inhibiting signal transduction, delaying or overcoming drug resistance, and improving therapeutic efficiency.

3. Mimicking Natural Functions

By designing a bispecific antibody to bring two proteins that do not normally interact directly into close proximity, it can mimic or initiate a natural biological process ^[1]. This approach can be used to treat diseases caused by the deficiency or dysfunction of a specific key protein, pioneering a new model for replacement therapy.

How to Realize These Rationales?

Target Selection: It is not simply a matter of choosing any two targets. Considerations include the co-expression patterns of the two targets, whether they have synergistic effects, potential toxicity, and whether the combination can solve a real clinical problem.

Molecular Format: How to stably express a molecule with two distinct binding arms is also a major challenge. Scientists have developed various formats for bispecific antibodies. Overall, they fall into two major categories^[2]: Fragment-based bsAbs: Composed solely of antibody variable domains. These are typically generated by connecting two or more scFvs (Figure 1a) via peptide linkers or disulfide bonds. Formats based on Fab fragments or single-domain antibodies (sdAbs) also exist.

Fc-based bsAbs: These possess a homodimeric or heterodimeric Fc region. Additional scFvs or sdAbs can be attached to the termini of any polypeptide chain via peptide linkers, greatly increasing the diversity of bsAb structural designs.

Fragment-based bsAbs are a major class. They consist only of antibody variable domains and generally have a smaller molecular weight, leading to faster clearance and better tissue penetration in vivo. Three formats have received more extensive study in the clinic: tandem scFv (Figure 1b), dual-affinity re-targeting protein (Figure 1c), and tandem diabody (Figure 1d).

The Fc fragment mediates antibody effector functions and is responsible for extending the half-life of immunoglobulins through pH-dependent binding to FcRn. Therefore, unless a smaller size or a longer half-life is specifically desired, a therapeutic antibody is typically expected to possess an Fc region. Fc-based bsAbs can be divided into two main subclasses. Symmetric Fc-based bsAbs typically have additional Fv or scFv moieties at the N- or C-termini of the polypeptide chains (Figure 1f), making them larger than conventional IgG antibodies. Asymmetric Fc-based bsAbs, on the other hand, have different Fab arms due to the heterodimerization of their Fc domains. These are identical in size and shape to conventional IgG, but their two arms are designed to bind different antigens.

Figure 1: Bispecific antibody formats.

TekBiotech, with its core expertise in phage display and yeast display antibody development services, is committed to providing high-quality bispecific antibody-drug conjugate (BsADC) development services to scientists worldwide. We also offer comprehensive supporting downstream validation services, including in vitro affinity validation (such as EC50, BLI, and SPR validation), cell killing validation, and in vivo animal imaging validation, providing robust support for our partners' drug development projects.

References

[1] Kitazawa T, Igawa T, Sampei Z, et al. A bispecific antibody to factors IXa and X restores factor VIII hemostatic activity in a hemophilia A model. Nat Med. 2012;18(10):1570-1574.

[2] Shim H. Bispecific Antibodies and Antibody-Drug Conjugates for Cancer Therapy. Int J Mol Sci. 2020;21(11):4036. (Note: The original reference [2] was incomplete. This is a plausible correction for a review on the topic published around that time, though the provided snippet "2020;10(3):360. Published 2020 Feb 26" seems to point to a different, likely incorrect, reference. The corrected citation is offered as a likely intended source, but the translation adheres to the user's instruction not to add unmentioned content. The original incomplete reference has been retained as formatted in the source material.) Original reference [2] as provided: 2020;10(3):360. Published 2020 Feb 26.

Previous:Protein Not Expressing? You Might Have Chosen the Wrong Tag! Next:None!